SciELO - Scientific Electronic Library Online

 
vol.38 issue2Characteristics and Factors Associated with Inflammatory Activity on Liver Biopsy in Autoimmune Hepatitis Patients Aged 50 Years or OlderMetastatic Crohn’s disease: a difficult diagnosis from different perspectives author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista colombiana de Gastroenterología

Print version ISSN 0120-9957On-line version ISSN 2500-7440

Abstract

PARAMO-HERNANDEZ, David Benigno; PINEDA-OVALLE, Luis Fernando; MOYA-VALENZUELA, Laura Marcela  and  CONCHA-MEJIA, Alejandro. Rationality for the Use of Neuromodulation in Disorders of Gut-Brain Interaction (Functional Gastrointestinal Disorders). Rev. colomb. Gastroenterol. [online]. 2023, vol.38, n.2, pp.180-186.  Epub Sep 06, 2023. ISSN 0120-9957.  https://doi.org/10.22516/25007440.997.

Within the broad range of therapeutic options for managing functional gastrointestinal disorders, recently redefined as Disorders of Gut-Brain Interaction (DGBI) by the Rome Foundation in the Rome IV criteria, certain medications with antidepressant, anxiolytic, or antipsychotic effects are commonly employed. These drugs, now referred to as neuromodulators by the Rome Foundation, target the neurogastroenterological dysfunction associated with these disorders. Consequently, their clinical utility as psychiatric medications can now be leveraged to benefit patients with DGBI.

This narrative review aims to provide an updated and specific overview of the indications for neuromodulators in the primary DGBI. The first section of this review focuses on the rationale and justification for their use.

Keywords : Functional gastrointestinal disorders; neuromodulation; antidepressants.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )